P1–351: A novel BACE inhibitor (PF‐05297909): A two‐part adaptive design to evaluate safety, pharmacokinetics and pharmacodynamics for modifying beta‐amyloid in a first‐in‐human study
J. Simon Bell(Monash University), Timothy Nicholas(Pfizer (United States)), Michael A. Brodney(Vertex Pharmaceuticals (United States)), David Riddell(Eli Lilly (United States)), Sebastian Ueckert(Uppsala University), Brian T. O’Neill(Pfizer (United States)), Éva Hajós‐Korcsok(Pfizer (United States)), Yasong Lu(Pfizer (United States)), Kaori Ito(Tokyo University of Agriculture and Technology)
Cited by 10
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Thermodynamic determination of fragility in liquids and a fragile-to-strong liquid transition in water
|Nature|1999|776
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302